Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 2/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005408 | 0.94 | KDM4E (0.51) | OPRM1KDM4ESMN1; SMN2ALDH1A1CHRM2 | |
| SCHEMBL1641009 | 0.85 | KDM4E (0.67) | OPRM1KDM4ESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL23111614 | 0.84 | TSHR (0.54) | KDM4ESMN1; SMN2LMNAALDH1A1CYP1A2 | |
| SCHEMBL2924537 | 0.83 | KDM4E (0.70) | KDM4ESMN1; SMN2CFTRLMNAALDH1A1 | |
| SCHEMBL1427498 | 0.83 | KDM4E (0.70) | OPRM1KDM4ESMN1; SMN2LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1238937 | 0.82 | KDM4E (0.68) | KDM4ESMN1; SMN2CFTRLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL15568255 | 0.82 | KDM4E (0.68) | KDM4ESMN1; SMN2CFTRLMNAALDH1A1 | |
| SCHEMBL2961101 | 0.81 | KDM4E (0.49) | KDM4ESMN1; SMN2LMNAALDH1A1CYP1A2 | |
| SCHEMBL20680180 | 0.81 | HTR6 (0.49) | OPRM1KDM4ESMN1; SMN2GPR183ALDH1A1 | |
| SCHEMBL20971765 | 0.81 | CXCR3 (0.57) | OPRM1KDM4ESMN1; SMN2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019194769-A2 | ANTI CANCER AND ANTI TYROSINASE ACTIVITIES OF KOJIC ACID DERIVED COMPOUNDS | AYTEMIR MUTLU (TR) | 2019-10-10 | — | — | WO | disclosed |
| US-9192569-B2 | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9006392-B2 | Actagardine derivatives, and pharmaceutical use thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-9006392-B2 | Actagardine derivatives, and pharmaceutical use thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| EP-2231619-B1 | INHIBITORS OF STEAROYL-COA DESATURASE | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| EP-2231619-B1 | INHIBITORS OF STEAROYL-COA DESATURASE | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2603204-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | Novacta Biosystems Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-05-30 | — | — | US | disclosed |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| WO-2011095769-A1 | ACTAGARDINE DERIVATIVES, AND PHARMACEUTICAL USE THEREOF | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| CN-101896473-A | Inhibitors of stearoyl-coa desaturase | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| EP-2231619-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | disclosed |
| US-7652013-B2 | Inhibitors of stearoyl-CoA desaturase | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652013-B2 | Inhibitors of stearoyl-CoA desaturase | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2009074487-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074487-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | GILLESPIE PAUL | 2009-06-11 | — | — | US | disclosed |
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | GILLESPIE PAUL | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | OPRM1 2342/4885KDM4E 856/4885SMN1; SMN2 1950/4885 |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | SLC5A2, SLC5A11, SPTSSB | OPRM1 4393/4885KDM4E 4468/4885SMN1; SMN2 1392/4885 |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | GALR2, GALR1, GALR3 | OPRM1 233/4885KDM4E 4791/4885SMN1; SMN2 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.